Press release
Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced
An investigation on behalf of investors in BioAtla, Inc. (NASDAQ: BCAB) shares over potential wrongdoing at BioAtla, Inc.
Investors who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain BioAtla, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. reported that its Net Loss increased from $95.4 million in 2021 to $106.48 million in 2022.
Shares of BioAtla, Inc. (NASDAQ: BCAB) declined from $4.31 per share in February 2023 to as low as $1.42 per share in October 2023.
Those who purchased shares of BioAtla, Inc. (NASDAQ: BCAB) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation for Investors in BioAtla, Inc. (NASDAQ: BCAB) over potential Wrongdoing announced here
News-ID: 3531401 • Views: …
More Releases from Shareholders Foundation, Inc.
Ready Capital Corporation (NYSE: RC) Long Term Investor Investigation of potenti …
An investigation was announced for potential breaches of fiduciary duties by certain directors and officers of Ready Capital Corporation.
Investors who are current long term investors in Ready Capital Corporation (NYSE: RC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: RC stocks follows a lawsuit filed against Ready…
Investigation announced for Long-Term Investors in shares of Digimarc Corporatio …
An investigation was announced for current long-term investors in shares of Digimarc Corporation (NASDAQ: DMRC) concerning potential breaches of fiduciary duties by certain directors of Digimarc Corporation.
Investors who are current long term investors in Digimarc Corporation (NASDAQ: DMRC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: DMRC…
Ultra Clean Holdings, Inc. (NASDAQ: UCTT) Investor Alert: Deadline in Lawsuit on …
A deadline is coming up on May 23, 2025 in the lawsuit filed for certain investors of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) over alleged securities laws violations by Ultra Clean Holdings, Inc.
Investors who purchased shares of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) have certain options and there are strict and short deadlines running. Deadline: May 23, 2025. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) stockholders should contact the Shareholders…
Lawsuit filed for Investors who lost money with shares of West Pharmaceutical Se …
An investor, who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST), filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by West Pharmaceutical Services, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of West Pharmaceutical Services, Inc. (NYSE: WST) have certain options and for certain investors are short and strict deadlines running.…
More Releases for BioAtla
Oncology Antibody Drug Conjugates Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027.
Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical,…
Global Synovial Sarcoma (SS) Market Scope Report Forecast to 2021-27 |key player …
Synovial sarcoma (SS) is a disease that can begin from various sorts of delicate tissue, like muscle or tendons. It is normally found in the arm, leg, or foot and close to joints like the wrist or lower leg. It can likewise frame delicate tissues in the lung or mid-region.
Coronavirus first appeared in China at the end of 2019. We anticipate that the global economy's growth rate will come in…
Global CAR-T Therapy Treatment Market Overview, Industry Top Manufactures, Size, …
Global CAR-T Therapy Treatment Market is a professional and exhaustive report which focuses on primary and secondary drivers, market share, leading segments and geographical analysis. This market research report contains fundamental, secondary and advanced information related to the global status and trend, market size, sales volume, market share, growth, future trends analysis, segment and forecasts from 2021 – 2028. The report acts as a supreme base for the competitor analysis,…
CAR-T Cell Therapy Treatment Market 2021:Size,Trends,Growth Rate,Developments, a …
“Global CAR-T Cell Therapy Treatment Market- Industry Trends and Forecast to 2028” Worldwide Industry Size, Offer and trends analysis during Period. CAR-T Cell Therapy Treatment Market report is a thoughtful analysis of the market presenting the propelled situation in the market and additionally plots that guide in its expansion in the coming years. The CAR-T Cell Therapy Treatment report assesses a few elements are deciding the market development and additionally…
CAR-T Therapy Treatment Market 2020-2027 Share, Growth, Trends, And Covid-19 : P …
Global CAR-T therapy treatment market is rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide where CAR-T cell therapies act as a dominant treatment and new launches of the product are the key factors for market growth.
Request for FREE Sample Copy or PDF Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-car-t-therapy-treatment-market
Few of the major competitors currently working in the global CAR-T therapy treatment market are Novartis AG, Gilead Sciences, Inc, AbbVie Inc,…
CAR-T Therapy Treatment Market - Global Drivers, Restraints, Opportunities, Tren …
With the nice combination of hard work of skilled forecasters, well-versed analysts and knowledgeable researchers, such premium outcome, in the form of CAR-T Therapy Treatment market research report can be attained. By clearly identifying and analysing the emerging trends in the market, this market report also explains major drivers, challenges and opportunities in the market for Healthcare industry. The report endows with the wide-ranging statistical analysis of the market's constant…
